Future approaches to clearing the latent human immunodeficiency virus reservoir: Beyond latency reversal

Future approaches to clearing the latent human immunodeficiency virus reservoir: Beyond latency reversal

Background: While combined antiretroviral therapy (cART) allows near-normal life expectancy for people living with human immunodeficiency virus (HIV), it is unable to cure the infection and so life long treatment is required. Objectives: The main barrier to curing HIV is the latent reservoir of cel...

Full description

Bibliographic Details
Main Author:	Alexander M.L. Hayes
Format:	Article
Language:	English
Published:	AOSIS 2020-08-01
Series:	Southern African Journal of HIV Medicine
Subjects:	hiv latency reversal viral reservoir pro-apoptotic drugs cart
Online Access:	https://sajhivmed.org.za/index.php/hivmed/article/view/1089

Similar Items

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies
by: Sushant Khanal, et al.
Published: (2021-02-01)

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
by: Amina Ait-Ammar, et al.
Published: (2020-01-01)

Targeting the brain reservoirs: towards an HIV cure
by: Celine Marban, et al.
Published: (2016-09-01)

NSC95397 Is a Novel HIV-1 Latency-Reversing Agent
by: Randilea Nichols Doyle, et al.
Published: (2024-11-01)

Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells
by: Emilie Battivelli, et al.
Published: (2018-05-01)

Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency
by: Alexander O. Pasternak, et al.
Published: (2023-04-01)

Corrigendum: Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency
by: Alexander O. Pasternak, et al.
Published: (2023-05-01)

Replication competence of virions induced from CD4+ lymphocytes latently infected with HIV
by: Douglas D. Richman, et al.
Published: (2019-02-01)

HIV LTR-Driven Antisense RNA by Itself Has Regulatory Function and May Curtail Virus Reactivation From Latency
by: Mie Kobayashi-Ishihara, et al.
Published: (2018-05-01)

A Canadian Survey of Research on HIV-1 Latency—Where Are We Now and Where Are We Heading?
by: Ana Luiza Abdalla, et al.
Published: (2024-02-01)

Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency
by: Jennifer M. Zerbato, et al.
Published: (2021-03-01)

Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment
by: Ignacio Relaño-Rodríguez, et al.
Published: (2019-05-01)

The cell biology of HIV-1 latency and rebound
by: Uri Mbonye, et al.
Published: (2024-04-01)

Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal
by: Mateusz Stoszko, et al.
Published: (2016-01-01)

Editorial: HIV Latency: novel insights into the viral reservoir and therapeutic strategies
by: Ana Carolina Soares de Oliveira, et al.
Published: (2024-06-01)

Coloring hidden viruses
by: Marina Lusic
Published: (2018-05-01)

The Proviral Reservoirs of Human Immunodeficiency Virus (HIV) Infection
by: Andrey I. Murzin, et al.
Published: (2024-12-01)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
by: Catherine A. Lewis, et al.
Published: (2023-07-01)

Targeting HIV-1 reservoirs in T cell subsets
by: Min Li, et al.
Published: (2023-01-01)

Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment
by: Xu-Sheng Huang, et al.
Published: (2022-03-01)

Effective and targeted latency reversal in CD4+ T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection
by: Minh Ha Ngo, et al.
Published: (2024-12-01)

Experimental Systems for Measuring HIV Latency and Reactivation
by: Koh Fujinaga, et al.
Published: (2020-11-01)

Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation
by: Alberto Bosque, et al.
Published: (2017-01-01)

Compounds producing an effective combinatorial regimen for disruption of HIV‐1 latency
by: Pargol Hashemi, et al.
Published: (2017-12-01)

Implications of HIV-1 Nef for “Shock and Kill” Strategies to Eliminate Latent Viral Reservoirs
by: Xiaomei T. Kuang, et al.
Published: (2018-11-01)

Bioactive Compounds from <i>Euphorbia usambarica</i> Pax. with HIV-1 Latency Reversal Activity
by: Yu-Chi Tsai, et al.
Published: (2021-07-01)

Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products
by: Khumoekae Richard, et al.
Published: (2018-06-01)

Croton oligandrus Pierre & Hutch (Euphorbiaceae) Extracts and Isolated Compounds Reverse HIV-1 Latency
by: Emade Nkwelle C, et al.
Published: (2024-11-01)

Lnc(ing)RNAs to the “shock and kill” strategy for HIV-1 cure
by: Saikat Boliar, et al.
Published: (2021-03-01)

Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
by: Amanda B. Macedo, et al.
Published: (2019-10-01)

The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency
by: Lesley R. de Armas, et al.
Published: (2021-08-01)

Post-Transcriptional HIV-1 Latency: A Promising Target for Therapy?
by: Mie Kobayashi-Ishihara, et al.
Published: (2024-04-01)

The mouse viral outgrowth assay: avatars for the detection of HIV-1 reservoirs
by: Kelly A. Metcalf Pate, et al.
Published: (2017-11-01)

HIV Latency in Myeloid Cells: Challenges for a Cure
by: Alisha Chitrakar, et al.
Published: (2022-05-01)

The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication
by: Victoria E. Walker-Sperling, et al.
Published: (2016-06-01)

HIV Persistence, Latency, and Cure Approaches: Where Are We Now?
by: Tessa C. Chou, et al.
Published: (2024-07-01)

Targeting Viral Transcription for HIV Cure Strategies
by: Jon Izquierdo-Pujol, et al.
Published: (2024-04-01)

Noncanonical-NF-κB activation and DDX3 inhibition reduces the HIV-1 reservoir by elimination of latently infected cells ex-vivo
by: Jade Jansen, et al.
Published: (2024-01-01)

HIV Latency Reversing Agents have diverse effects on Natural Killer Cell Function
by: Carolina Garrido, et al.
Published: (2016-09-01)

Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a Cure
by: Natasha N. Duggan, et al.
Published: (2023-12-01)